CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: October 26, 2006
Result type: Reports
Project Number: SR0081-000
Product Line: Reimbursement Review

Generic Name: Deferasirox

Brand Name: Exjade

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Therapeutic Area: Iron overload

Indications: Iron overload

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: April 19, 2007

Recommendation Type: List with clinical criteria and/or conditions